Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 671 to 680 of 1443 total matches.

Antiviral Drugs

   
Treatment Guidelines from The Medical Letter • Mar 01, 2013  (Issue 127)
information call: 800-211-2769 Antiviral Drugs Treatment Guidelines from The Medical Letter • Vol. 11 (Issue ...
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Treat Guidel Med Lett. 2013 Mar;11(127):19-30 | Show Introduction Hide Introduction

Cancer Screening

   
Treatment Guidelines from The Medical Letter • Dec 01, 2012  (Issue 124)
from The Medical Letter • Vol. 10 (Issue 124) • December 2012 Use of screening tests to identify cancers before ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec;10(124):87-94 | Show Introduction Hide Introduction

Antifungal Drugs

   
Treatment Guidelines from The Medical Letter • Aug 01, 2012  (Issue 120)
Drugs 62 Treatment Guidelines from The Medical Letter • Vol. 10 ( Issue 120) • August 2012 Table 1 ...
The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).
Treat Guidel Med Lett. 2012 Aug;10(120):61-8 | Show Introduction Hide Introduction

Drugs for Tuberculosis

   
Treatment Guidelines from The Medical Letter • Apr 01, 2012  (Issue 116)
from The Medical Letter • Vol. 10 (Issue 116) • April 2012 These reports include cases of extrapulmonary ...
Tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses challenges to its treatment and control. Guidelines with detailed management recommendations are available from the American Thoracic Society, Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA).
Treat Guidel Med Lett. 2012 Apr;10(116):29-36 | Show Introduction Hide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
from The Medical Letter • Vol. 7 (Issue 84) August 2009 with 50-100 mcg/day, but others begin with full ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 | Show Introduction Hide Introduction

Drugs for Cardiac Arrhythmias

   
Treatment Guidelines from The Medical Letter • Jun 01, 2007  (Issue 58)
is hemodynamically stable) or DC cardioversion. Vol. 5 (Issue 58) June 2007 Published by The Medical Letter ...
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Treat Guidel Med Lett. 2007 Jun;5(58):51-8 | Show Introduction Hide Introduction

Erythropoietin Safety Concerns

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
in Oncology. Cancer- and treatment-related anemia. Vol. 3 2007. Available at www.nccn.org/professionals ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Med Lett Drugs Ther. 2007 May 7;49(1260):37-9 | Show Introduction Hide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
or decreased motility. 4 Vol. 4 (Issue 49) September 2006 Published by The Medical Letter, Inc. 1000 ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 | Show Introduction Hide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
chemotherapy with 5-FU and cisplatin (FUP) may be the most widely used, but has substantial toxicity. Vol. 4 ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 | Show Introduction Hide Introduction

Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
2006 1234 osteoporosis Postmenopausal volume 48 vol. 48 vol 48 treatment of breast cancer Tamoxifen ...
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and others) for prevention of breast cancer in high-risk postmenopausal women.
Med Lett Drugs Ther. 2006 May 8;48(1234):37 | Show Introduction Hide Introduction